What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Acquired immunodeficiency syndrome
- Surgery
His primary areas of investigation include Internal medicine, Immunology, Odds ratio, Virology and Reverse-transcriptase inhibitor.
His Internal medicine research integrates issues from Gastroenterology, Lipodystrophy, Endocrinology and Viral load.
His Immunology course of study focuses on Cohort and Cancer, Immunodeficiency, Genome-wide association study, Coronary artery disease and Family history.
His Odds ratio research incorporates elements of Incidence, Confidence interval, Complication, Immunopathology and Meningococcal disease.
Paracrine signalling, Mitochondrion and Hormone is closely connected to Nucleoside Reverse Transcriptase Inhibitor in his research, which is encompassed under the umbrella topic of Virology.
His research in Reverse-transcriptase inhibitor focuses on subjects like Nevirapine, which are connected to Dosing and HIV-associated lipodystrophy.
His most cited work include:
- HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects (470 citations)
- Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. (274 citations)
- Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. (272 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Immunology, Gastroenterology, Virology and Surgery are his primary areas of study.
Pere Domingo has included themes like Lipodystrophy, Endocrinology, Viral load and Ritonavir in his Internal medicine study.
His Lipodystrophy research is multidisciplinary, relying on both Adipose tissue, Stavudine and Lipoatrophy.
His study on Immunology also encompasses disciplines like
- Odds ratio that connect with fields like Confidence interval,
- Cohort study most often made with reference to Cohort.
Pere Domingo has researched Gastroenterology in several fields, including Lamivudine, Adverse effect and Hepatitis C virus.
Pere Domingo works in the field of Virology, namely Reverse-transcriptase inhibitor.
He most often published in these fields:
- Internal medicine (46.65%)
- Immunology (20.98%)
- Gastroenterology (15.85%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (46.65%)
- Immunology (20.98%)
- Ritonavir (10.04%)
In recent papers he was focusing on the following fields of study:
Pere Domingo mainly focuses on Internal medicine, Immunology, Ritonavir, Antiretroviral therapy and Pharmacology.
His research in Internal medicine intersects with topics in Gastroenterology, Endocrinology and Viral load.
His work in Immunology covers topics such as Proportional hazards model which are related to areas like Hazard ratio, Confidence interval and Oncology.
His research on Ritonavir also deals with topics like
- Lopinavir which connect with Lopinavir/ritonavir,
- Emtricitabine which connect with Efavirenz and Raltegravir,
- Darunavir that intertwine with fields like Randomized controlled trial,
- Virology most often made with reference to Protease inhibitor.
Pere Domingo interconnects Elvitegravir, Cobicistat and Renal function in the investigation of issues within Pharmacology.
His work in Regimen tackles topics such as Acquired immunodeficiency syndrome which are related to areas like Pediatrics.
Between 2013 and 2021, his most popular works were:
- Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial (76 citations)
- FGF19 and FGF21 serum concentrations in human obesity and type 2 diabetes behave differently after diet- or surgically-induced weight loss (64 citations)
- Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. (58 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Acquired immunodeficiency syndrome
- Cancer
Pere Domingo mostly deals with Internal medicine, Ritonavir, Endocrinology, Gastroenterology and Immunology.
His specific area of interest is Internal medicine, where Pere Domingo studies Regimen.
The study incorporates disciplines such as Protease inhibitor, Lopinavir and Cholesterol in addition to Ritonavir.
His Endocrinology research incorporates themes from FGF21 and Inflammation.
The various areas that Pere Domingo examines in his Gastroenterology study include Lean body mass, Case-control study and Bone mineral, Peak bone mass, Osteoporosis.
His Immunology research includes elements of Infectious disease and Proportional hazards model.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
